Søgning på udtrykket 'hiv' giver 164 resultater


Dokumenter [17] Sider [7] Kalender [91] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]

Dokumenter [17]

Forfattere: Jan Gerstoft, Nina Weis, Terese L. Katzenstein (Dansk Selskab for Infektionsmedicin), Anders Nyboe Andersen og Jens Fedder (Dansk Fertilitetsselskab).

Version: 3. Endelig guideline: 01.09.2020. Guideline skal revideres senest: 01.09.2023 Arbejdsgruppens medlemmer: Peer Brehm Christensen, Christian Erikstrup, Jan Gerstoft, Terese Katzenstein, Alex Laursen, Suzanne Lunding, Birgitte Mørn og Nina Weis.

Arbejdsgruppen bestod af: Jan Gerstoft, Ann-Brit Eg Hansen, Gitte Kronborg, Jens D. Lundgren, Henrik I. Nielsen, Olav Ditlevsen Larsen, Niels Obel og Alex Laursen

Fællesregional retningslinje for udlevering af forebyggende medicin mod HIV (PrEP), udgivet af Danske Regioner.

…medicin i form af f.eks TNF-α hæmmere eller andre immunsupprimerende biologiske lægemidler, hvor der er øget risiko for tuberkulosereaktivering. Guideline dækker ikke børn, personer med medfødt immundefekt, HIV positive, patienter i dialyse, patienter med dysreguleret diabetes, silicose, erhvervede immundefekter eller patienter i konventionel kortvarig kemoterapi. Denne guideline omhandler ikke klassisk smitteopsporing blandt tuberkuloseeksponerede eller udredning på mistanke om aktiv tuberkulose.

…r (BMSL) til patienter i forhold til risiko for tuberkulose (TB), Humant Papillom Virus (HPV), Hepatitis B og C (HBV og HCV), Varicella Zoster Virus (VZV), Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV) og Humant Immundefekt Virus (HIV) og øvrige infektioner. Vejledningen er udarbejdet af repræsentanter fra Dansk Selskab for Gastroenterologi og Hepatologi (DSGH), Dansk Reumatologisk Selskab (DRS), Dansk Dermatologisk Selskab (DDS) og Dansk Selskab for Infektionsmedicin (DSI).

Europæisk guideline om hvornår, der bør testes for HIV. Udgivet af "HIV in Europe", et paneuropæisk initiativ for tidligere diagnosticering og behandling af HIV. Kort version på dansk kan findes på www.eurotest.org/projects-collaborations/indicator-condition-guided-hiv-testinghides/guidance-hiv-indicator-conditions

Revideret september 2020. Arbejdsgruppen bestod af Suzanne Lunding (formand), Peer Brehm Christensen, Christian Erikstrup, Terese L. Katzenstein, Henrik Krarup, Alex Lund Laursen, Birgitte Mørn og Nina Weis

Udarbejdet af DSI's arbejdsgruppe vedrørende antiretroviral terapi

Arrangeret af Yngre Infektionsmedicinere

Correspondence regarding "Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy"

Senest revideret september 2021 . Arbejdsgruppen bestod af: Jan Gerstoft, Gitte Kronborg , Ann Brit Eg Hansen, Jens D. Lundgren, Henrik I. Nielsen, Olav Ditlevsen Larsen , Niels Obel og Alex Laursen

Forfattet af DSI's arbejdsgruppe vedrørende antiviral behandling

Bilag til Retningslinjer for screening og profylakse før behandling med biologiske lægemidler (2023)

Sider [7]

…nter 1). Kort over Hvidovre Hospital: www.hvidovrehospital.dk/praktisk-information/transport/Documents/Kort%20over%20Hvidovre%20Hospital.pdf. Delkursusledere: Ole Søgård og Lene Ryom. Formål: At kursisten skal opnå en forståelse af HIV-infektionen, herunder viden om dens epidemiologi, patogenese, diagnose, forebyggelse, behandlingsmulighederne og prognose. Derudover at opnå viden om diagnostik og behandlingen af AIDS-definerende sygdomme og af de hyppigste komorbiditeter hos dem, de…

Formål: At kursisten skal opnå en forståelse af HIV-infektionen herunder viden om dens epidemiologi, patogenese, patofysiologi, diagnose, forebyggelse, behandlingsmuligheder og prognose samt viden om diagnostik og behandlingen af AIDS-definerende sygdomme og de hyppigste sexuelt overførte sygdomme. Tid og sted: Hvidovre Hospital. Lokale 10 i undervisningsbygningen. Delkursusledere: Ann-Brit Eg Hansen og Ole Kirk. Program: Mandag 3. oktober: 10:00-10:15 Velkomst og introduktion (Ann-…

…me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet. Alvorlige sygdomme som hæmoragisk viral feber forårsaget af Ebola, Lassa, Dengue, Crimean-Co…

…epatitis: Carsten Shade Larsen og Nina Weis. Hepatitis A (2013), Antiretroviral terapi: Henrik Nielsen, Jan Gerstoft, Jens Lundgren, Alex Laursen, Niels Obel, Isik Somuncu, Gitte Kronborg, Ann-Brit Eg Hansen Antiviral behandling af hiv smittede personer (2021), Fertilitetsbehandling ved HIV og hepatitis B og C (2018), HIV behandling af gravide (2021), HIV post exposure profylakse (2020), Pre-exposure profylakse mod HIV (2021), Borrelia: Anne-Mette Lebech (tovho…

…terologiske infektioner og kronisk hepatitis: Dato for næste kursus 2026: Sted Odense Universitetshospital Delkursusledelse Lone Mygind, Micha Jepsen og Belinda Mössner Tidligere kurser 4. og 5. december 2023 3. og 4. december 2020 HIV-infektion: Næste kursus Efterår 2025 (2 dage): Sted Afventer Delkursusledelse Ole Schmeltz Søgaard og Lene Ryom Nielsen  Program Afventer Tidligere kurser 12. og 13. oktober 2022 7. og 8. oktober 2019 3. og 4. oktober 2016 …

…me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet. Alvorlige sygdomme som hæmoragisk viral feber forårsaget af Ebola, Lassa, Dengue, Crimean-Co…

…iklen summerer på en rimelig afbalanceret måde den globale kontrovers, som 2013 var præget af, om hvorvidt ART skal benyttes som forebyggende middel, som led i en individuel-baseret eller en folkesundsbaseret strategi for at reducere smittespredning af HIV. De udfordringer som den vestlige verden, trods udbredt og gratis behandlingstilbud, har med at få styr på smittespredning blandt fx mænd-der-har-sex-med-mænd viser, at det - der intuitivt synes ligefor - ikke nødvendigvis virker når det kommer t…

Professor Henrik Nielsen kommenterer: Trods indiskutable fremskridt i den farmakologiske behandling af HIV/AIDS er der fortsat områder med plads til forbedring. Blandt patienter i kronisk behandling er HAND (HIV-associated neurocognitive disorder) et af disse eksempler. Det har været debatteret om forskelle i antiretrovirale lægemidlers penetrans over blod/hjerne barrieren har betydning for HAND og for AIDS-definerende opportunistisk infektion i hjernen. Der er ingen tvivl om at koncentr…

Professor Jens Lundgren kommenterer: I 2014 var verden optaget af Ebola udbruddet i Vest Afrika – et udbrud der blev erkendt hurtigt (om end den internationale assistance lod vente på sig). Vedlagte artikel belyser detaljeret hvorledes HIV pandemien startede i 1920’erne og hvor det jo som bekendt tog over 60 år af finde ud at der overhovedet var et problem. Synes artiklen er godt skrevet og giver et indblik i Afrika for 90 års siden og de ingredienser der skulle til for at ud…

Professor Lars Østergaard kommenterer: Jeg vil gerne anbefale vedlagte artikel som julemånedslæsning. Grundene er som følger: 1) Det vises for første gang, at et medikament kan reaktivere latent HIV-virus under samtidig HAART-behandling i en grad, så virus kan påvises i perifert blod. 2) Der er (omend videnskaligt svage) indicier på, at HIV-reservoir kan reduceres hos nogle patienter, og at effekten af det innate immunforsvar er af betydning herfor. 3) Det er den første originalartikel trykt i den …

Professor Jens Lundgren kommenterer: I 2015 nåede WHO sit mål om at få 15 million på behandling. START studiet afklarede også at alle HIV+ personer har gavn af at starte på HIV behandling. Der er fortsat mere end 20 millioner der endnu ikke er startet. Hovedparten bor i ressource svage lande hvor adgang til monitorering af HIV mængden er begrænset og behandlingsskift pga behandlingssvigt er derfor primært drevet af klinik og CD4 tals måling. Omkostning ifm nyttevirkning er central i at forbedre be…

… dolutegravir, især når det kombineres med TAF fremfor tenofovir DF, forårsager markant vægtøgning. Især hos kvinder med mørk hudfarve. Artiklen gør indtryk af en række grunde:. Da dolutegravir blev markedsført havde det profilen som det eneste HIV præparat uden bivirkninger. Læring: der er ingen medicinske præparater der ikke har nogle bivirkninger, og typen af bivirkninger kan ikke altid forudsiges udfra markedsføringsstudier (fase I-III). Dette faktum er universelt og set for praktisk tage…

Professor Jens Lundgren kommenterer: Første lægemiddel mod SARS-CoV-2 udviklet fra ”bunden” – bruger et gammel trick fra HIV medicinen (ritonavir) for at holde plasma koncentrationerne oppe. Læringen er, at det tager tid at lave nye lægemidler helt fra bunden, men det er noget nær en verdensrekord så hurtigt som det skete under pandemien – både hvad angår vacciner (hvor det tog < 1 år fra design ex vivo til markedsføring), men altså ca 2 år for lægemidler som dette.

Professor Lars Østergaard kommenterer: Indimellem kommer der studier, som er så overbevisende, at det sætter en ny behandlingsstandard. Det kan f.eks. være Lundgrens studie af, hvornår man kan holde op med at give pneumocyste-profylakse til HIV-smittede eller de Gans studiet, der ændrede fik indført dexamethason i retningslinjerne for purulent meningitis. Her er formentlig et nyt studie, der kommer til at få indflydelse på standardbehandlingen af patienter med svær pneumoni. Læs en gang - og d…

Professor Troels Lillebæk kommenterer: Interessant systematisk review i AIDS om udbytte af screening for tuberkulose infektion (TBI) blandt personer, der lever med HIV (PLHIV) i tuberkulose lav-incidens lande (som Danmark) . Inddraget i alt 51 undersøgelser med 65.930 PLHIV hvoraf 12 % havde en positiv LTBI-test, som var stærkt relateret til oprindelsesland og eksponering for TB ). Forfatterne beretter at 20 TBI-positive personer skulle behandles for at forhindre ét tilfælde af TB, og at antallet, der …


Kalender [91]

27. oktober, Glasgow, Skotland
3. april, Online
21. marts, Fredericia
27. september 2023, Stockholm, Sverige
24. august 2023, Emil Aarestrup Auditorium, Odense Universitetshospital
23. juli 2023, Brisbane, Australien og virtuelt
7. juni 2023, Rom, Italien
1. juni 2023, Mærsk Tårnet, Panum Instituttet, København
27. januar 2023, Karen Brahe auditoriet, Odense Adelige Jomfrukloster (og online)
14. december 2022, Statens Institut for Folkesundhed og online
23. oktober 2022, Glasgow, Skotland
20. oktober 2022, Washington DC, USA
12. oktober 2022, Hvidovre Hospital
28. september 2022, Stockholm, Sverige
22. september 2022, Barcelona, Spanien
10. juni 2022, Panum, København
17. maj 2022, Niels K. Jerne auditoriet, Panum Instituttet, København
6. december 2021, Rigshospitalet
26. november 2021, Panum, København
30. september 2021, Barcelona, Spanien
23. marts 2021, Online
28. oktober 2020, Paris, Frankrig
25. oktober 2020, Glasgow, Skotland
28. august 2020, Online og Henrik Dam auditoriet, Maersk Tårnet
10. marts 2020, KolleKolle, Værløse
7. oktober 2019, København
11. september 2019, DGI-byen, København
22. maj 2019, Rom, Italien
13. maj 2019, København, Odense, Aarhus
6. marts 2019, KolleKolle, Værløse
2. november 2018, Mærsk Tower, København
28. oktober 2018, Glasgow, Skotland
30. maj 2018, Rom, Italien
4. maj 2018, Hindsgavl, Middelfart
16. marts 2018, Værløse
28. februar 2018, Nielsine Nielsen Auditorium, Mærsk Tårnet, København
23. februar 2018, Syddansk Universitet, Odense
1. februar 2018, Nielsine Nielsen auditoriet, Mærsk Tårnet, København
6. oktober 2017, Holst Auditoriet, Mærsk tårnet, København
8. juni 2017, Hvidovre Hospital
4. maj 2017, Odense Universitetshospital
18. april 2017, Auditorium 93, Rigshospitalet
23. oktober 2016, Glasgow, Skotland
3. oktober 2016, Hvidovre Hospital
25. maj 2016, Rom, Italien
29. april 2016, Hindsgavl, Middelfart
7. januar 2016, Medicinsk Museion, København
18. december 2015, Emil Aarestrup auditorium, Odense Universitetshospital
24. november 2015, Hvidovre Universitetshospital
8. september 2015, Panum Instituttet, København
18. juni 2015, Rigshospitalet, Teilum B
12. juni 2015, Medicinsk Museion, København
3. juni 2015, Barcelona, Spanien
24. april 2015, Auditorium 93, Rigshospitalet
17. april 2015, Foredragssalen, Statens Serum Institut
19. marts 2015, Auditorium 1, Rigshospitalet
2. november 2014, Glasgow, Skotland
5. oktober 2014, Barcelona, Spanien
18. juni 2014, Store Auditorium, Winsløwparken 15, st., 5000 Odense C
22. april 2014, Auditorium 5, Hvidovre Hospital
26. marts 2014, Barcelona, Spanien
25. oktober 2013, Hannover auditoriet, Panum Instituttet, København
30. juni 2013, Kuala Lumpur, Malaysia
10. juni 2013, Centre for Medical Parasitology, København
3. maj 2013, Hindsgavl, Fyn
20. marts 2013, Rom, Italien
14. januar 2013, Auditorium 2, Rigshospitalet
10. november 2012, Auditorium 2, Rigshospitalet
25. oktober 2012, Danmarks Medie- og Journalisthøjskole
23. oktober 2012, Rigshospitalet
2. oktober 2013, San Francisco, USA
27. september 2012, Auditorium 1, Bartholinbygningen, bygning 1241, lokale 135, Aarhus Universitet
29. februar 2012, SSI, København
9. december 2011, Rigshospitalet, københavn
7. november 2011, Auditorium 93, Rigshospitalet
13. maj 2011, Panum instituttet, København
29. april 2011, Auditorium B, Skejby
12. april 2011, Auditorium 100, Campusvej 55, 5230 Odense M, Syddansk Universitet
30. november 2007, Panum Instituttet, København

Nyt fra tidsskrifterne [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?
BMC Infectious Diseases
13.04.2024
. Abstract. . Background. Tuberculosis (TB) and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) co-morbidity continues to be a serious worldwide health issue, particularly in Sub-Saharan Africa. Studies on the quality of life (QOL) of TB/HIV co-infected patients guide stakeholders on the delivery of patient-centred healthcare. This study evaluated QOL of TB/HIV co-infected individuals and its contr…
BMC Infectious Diseases
12.04.2024
. Abstract. . Background. The world is moving towards the third target of the Joint United Nations Programme on HIV/AIDS to ensure most people receiving antiretroviral therapy (ART) are virologically suppressed. Little is known about viral suppression at an undetectable level and the risk of viral rebound phenomenon in sub-Saharan Africa which covers 67% of the global HIV burden.This study aimed to investigate the proportion…
Proceedings of the National Academy of Sciences
10.04.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 15, April 2024.
Clinical Infectious Diseases
10.04.2024
Abstract . Background . Children living with HIV(CLWH) are at high risk of tuberculosis(TB) and face poor outcomes, despite antiretroviral treatment(ART). We evaluated outcomes in CLWH and HIV-uninfected children treated for non-severe TB in the SHINE trial.Methods . SHINE was a randomized trial that enrolled children aged
AIDS
7.04.2024
Objective: . With aging, people living with HIV (PLWH) have diminishing postural stability that increases liability for falls. Factors and neuromechanisms contributing to instability are incompletely known. Brain white matter abnormalities seen as hyperintense (WMH) signals have been considered to underlie instability in normal aging and PLWH. We questioned whether sway-WMH relations endured after accounting for potentially relevant demographic, physiological, and HIV-related variables. Design: . Mixed cr…
AIDS
7.04.2024
Objectives: . Expansion of ART and increases to life expectancy have led to aging among people living with HIV (PWH). Design: . Kenyan decisionmakers need accurate forecasts of the age distribution of PWH to inform future policies. Methods: . We developed a model of HIV in Kenya, calibrated to historical estimates of HIV epidemiology. We forecasted changes in population size and age distribution of new HIV infections and PWH under the status quo and under scale-up of HIV services. Results: . Without sca…
Retrovirology
7.04.2024
Transcriptionally latent forms of replication-competent proviruses, present primarily in a small subset of memory CD4+ T cells, pose the primary barrier to a cure for HIV-1 infection because they are the source o.
Journal of Acquired Immune Deficiency Syndromes
7.04.2024
Background: . The COVID-19 pandemic disrupted global economic and healthcare systems. People living with HIV (PLWH) represent a marginalized and stigmatized population who may have been particularly impacted. The purpose of this analysis was to describe the impact of the COVID-19 pandemic on PLWH in the United States. Setting: . United States. Methods: . We analyzed surveys of behavioral and clinical characteristics of PLWH residing in five states that participated in the Medical Monitoring Project betwe…
Journal of Acquired Immune Deficiency Syndromes
7.04.2024
Background: . This study tests behavioral economics incentives to improve adherence to antiretroviral treatment (ART), with one approach being low-cost. Setting: . 329 adults at Mildmay Hospital in Kampala, Uganda on ART for at least two years and showing adherence problems received the intervention for about 15 months until the study was interrupted by a nation-wide COVID-19 lockdown. Methods: . We randomized participants into one of three (1:1:1) groups: usual care (‘control’ group; n=109) or one o…
Journal of Acquired Immune Deficiency Syndromes
7.04.2024
Background: . Early evidence suggests long-acting injectable cabotegravir and rilpivirine (LA-CAB/RPV) may be beneficial for people with HIV (PWH) who are unable to attain viral suppression (VS) on oral therapy. Limited guidance exists on implementation strategies for this population. Setting: . Ward 86, a clinic serving publicly insured PWH in San Francisco . Methods: . We describe multi-level determinants of and strategies for LA-CAB/RPV implementation for PWH without VS, using the Consolidated Framewo…
Journal of Acquired Immune Deficiency Syndromes
7.04.2024
Objective: . Efavirenz (EFV) is commonly used in combination antiretroviral therapy (cART). However, in our previous study, many persons living with human immunodeficiency virus (HIV) exhibited ocular complications despite undergoing effective cART. Here, we aimed to determine the intraocular EFV concentrations in the vitreous and analyze the factors affecting viral load in the vitreous in patients with HIV-associated retinopathies. Design: . Observational, retrospective study. Methods: . Fourteen patien…
Journal of Acquired Immune Deficiency Syndromes
7.04.2024
Background: . People living with mental illness (PLMI) experience disproportionately high incidence of and vulnerability to HIV. Pre-exposure prophylaxis (PrEP) is an effective and safe HIV prevention method, but data regarding prescription to PLMI are lacking. Psychiatrists may serve as important points of access for PrEP prescription for PLMI. Methods: . We conducted a vignette-based study of residents in psychiatry and family medicine (FM) to assess likelihood of prescribing PrEP and assumptions about …
Journal of Acquired Immune Deficiency Syndromes
7.04.2024
Background: . Approximately 13% of persons with HIV (PWH) are unaware of their status. To help end HIV, it is important to understand the relationship between the rates of HIV testing and undiagnosed HIV infection. Setting: . Ending the HIV in the U.S. (EHE) jurisdictions . Methods: . Using 2021 data from the National HIV Surveillance System and the National HIV Prevention Program Monitoring and Evaluation system, we calculated estimated rates of undiagnosed HIV infections per 100,000 population and rate…
Clinical Microbiology and Infection
6.04.2024
Pneumocystis jirovecii pneumonia (PCP) is a common opportunistic infection among people living with HIV (PLWH), particularly among new and untreated cases. Several regimens are available for the prophylaxis of PCP including trimethoprim-sulfamethoxazole (TMP-SMX), dapsone-based regimens (DBRs), aerosolized pentamidine (AP), and atovaquone.
Journal of Infectious Diseases
5.04.2024
Abstract . Dysbiosis of the vaginal microbiome poses a serious risk for sexual HIV-1 transmission. Prevotella spp. are abundant during vaginal dysbiosis and associated with enhanced HIV-1 susceptibility; however, underlying mechanisms remain unclear. Here, we investigated the direct effect of vaginal bacteria on HIV-1 susceptibility of vaginal CD4+ T cells. Notably, pre-exposure to Prevotella timonensis enhanced HIV-1 uptake by vaginal T cells, leading to increased viral fusion and enhanced virus production…
Lancet
5.04.2024
Our intervention, initiated at EPI-2 and based on extended single-drug postnatal prophylaxis guided by point-of-care maternal viral load could be an important strategy for paediatric HIV elimination.
Clinical Infectious Diseases
4.04.2024
Abstract . Background . Since 2019, the World Health Organization has recommended dolutegravir-based antiretroviral therapy (ART) as the preferred regimen for HIV management. Large-scale programmatic transitioning to dolutegravir-based ART was subsequently implemented across Africa, often in the absence of recent viral load testing and without access to genotypic resistance testing (GRT) in case of viremia.Methods . This study assessed for emerging dolutegravir resistance in the routine care Viral Load Coho…
BMC Infectious Diseases
4.04.2024
. Abstract. . Background. Non-sputum-based tests are needed to predict or diagnose tuberculosis (TB) disease in people living with HIV (PWH). The enzyme indoleamine 2, 3-dioxygenase-1 (IDO1) is expressed in tuberculoid granuloma and catabolizes tryptophan (Trp) to kynurenine (Kyn). IDO1 activity compromises innate and adaptive immune responses, promoting mycobacterial survival. The plasma Kyn-to-Trp (K/T) ratio is a potentia…

Aktuelle smitsomme sygdomme [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?
Eurosurveillance latest updates
15.03.2024
. Background. Some migrant men who have sex with men (MSM) acquire HIV in France. . . Aims. We investigated, in migrant MSM receiving HIV care in France, the (i) rate of post-migration-HIV acquisition in France, (ii) delay between arrival and HIV acquisition and (iii) factors affecting HIV acquisition within 1 year after migration. . . Methods. This cross-sectional study focused on ≥ 18-year-old MSM born outside France, receiving HIV care in the Paris region. Information on migration history, …
Medscape Infectious Diseases
11.03.2024
Semaglutide improved MASLD in this population, and weight loss associated with its use resulted in no significant changes in physical function, according to two presentations at CROI. . Medscape Medical News
Medscape Infectious Diseases
8.03.2024
A nurse-led multicomponent strategy significantly reduced systolic blood pressure and non-HDL cholesterol in HIV patients and should be included in HIV primary care programs. . Medscape Medical News
Medscape Infectious Diseases
6.03.2024
The World Health Organization (WHO) said on Tuesday resistance to GSK's HIV drug dolutegravir has exceeded levels observed during its trials, citing observational and survey. . Reuters Health Information
Medscape Infectious Diseases
5.03.2024
The last attempt in a generation of HIV vaccine development ended in disappointment, but investigators are starting over because they believe the human body can make antibodies for HIV. . Medscape Medical News
Medscape Infectious Diseases
5.03.2024
President Joe Biden's administration on Monday urged a U.S. appeals court to preserve a federal mandate that requires health insurers to cover preventive care services. . Reuters Health Information
Medscape Infectious Diseases
28.02.2024
British drugmaker GSK said on Wednesday its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment,. . Reuters Health Information
Medscape Infectious Diseases
26.02.2024
The smallpox vaccine effectively induces immunity against mpox virus infection in patients with HIV, although patients with low lymphocyte counts require booster doses. . Medscape Medical News
Eurosurveillance latest updates
9.02.2024
…is in immunodeficient (ID) individuals are scarce. This population may present with atypical clinical symptoms, be infected by uncommon pathogens and develop poor outcomes. . . Aim. We aimed to describe the epidemiology of infectious encephalitis among HIV-negative ID patients. . . Methods. Patients from the ENCEIF (Etude Nationale de Cohorte des Encéphalites Infectieuses en France) prospective cohort meeting criteria for infectious encephalitis between January 2016 and December 2019 were included. W…
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This report examines the relationship between structural and psychosocial syndemic conditions and condomless anal intercourse among Black, White, and Hispanic transgender women from seven urban areas in the U.S.
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This report describes the association between experiences of certain forms of violence and harassment and suicidal ideation among transgender women and explores the moderation of the association by perceived social support.
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This report describes the prevalence of six discrimination types toward transgender women and the association between employment discrimination and sociodemographic characteristics, health care access, and health care use.
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This report identifies specific personal characteristics and social factors associated with the duration of homelessness among transgender women from seven urban areas in the U.S.
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This analysis explored demographic, health care, and economic correlates of nonprescription hormone use among transgender women from seven urban areas in the U.S.
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This report examines whether transgender women who report behaviors associated with HIV acquisition were more likely to have had discussions with their clinician about pre-exposure prophylaxis (PrEP) and used PrEP.
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This report describes 2019-2020 data and system methods from the National HIV Behavioral Surveillance Among Transgender Women.
Medscape Infectious Diseases
11.01.2024
New findings support starting tecovirimat treatment at the time of suspected mpox diagnosis in all people with HIV. . MDedge News
Medscape Infectious Diseases
1.12.2023
At least 450 patients at Mass General Brigham, Salem Hospital, near Boston are at risk of HIV and hepatitis infection, according to a lawsuit claiming negligent intravenous medication administration. . Medscape Medical News
Medscape Infectious Diseases
1.12.2023
Europe's advances in HIV prevention strategies, including PrEP and long-acting retrovirals, bring hope amidst persistent access challenges and disparities. . Medscape Medical News
Eurosurveillance latest updates
1.12.2023
. Background. The global distribution of HIV-1 subtypes is evolving, which is reflected in the Swedish HIV cohort. The subtype HIV-1A6, which may be prone to developing resistance to cabotegravir, is the most common subtype in Ukraine. . . Aim. We aimed to examine trends in HIV-1 subtype distribution in Sweden, with a special focus on HIV-1A6, and to describe the virology, demography and treatment of Ukrainian people living with HIV (PLWH) who migrated to Sweden in 2022. . . Methods. Data about PLWH in …

Nyhedsbrev

Skriv din email adresse og modtag nyheder om hjemmesiden.


© 2024 Dansk Selskab for Infektionsmedicin

CVR: 33634307

www.infmed.dk
Version: 2.12.2
PHP version: 8.0.30
Design: Christian Philip Fischer
Side indlæst på 0.738 s

Cookies og privatliv